MabVax Therapeutics Holdings Inc
MabVax Therapeutics — Investor Presentation (August 2017)
33 slides from MabVax Therapeutics's investor presentation, Aug 24, 2017

Slide 1: Corporate Presentation August 2017
\y/ MabVax therapeutics Corporate Presentation August 2017 NASDAQ: MBVX ‘wirenabvatlae

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warranty as to the completeness of this information or, inthe case of the projections, as to their attainabilty or the accuracy and completeness

Slide 3: Table of Contents
M Table of Contents + Company Overview + Management Team & Board of Directors * Discovery Platform + Clinical Pipeline + Safety & Efficacy Data + Development Plan * Corporate

Slide 4: Company Overview
Company Overview Fully-Human Antibody | | MabVaxis an antibody discovery and development company with products that were Discovery Platform | discovered from the immune response of cancer patients Clinical stage Developmant Company | | Thee active Phase 1 clinica rials targeting CA19-9 positive mali

Slide 5: Management Team
Management Team J. David Hansen _ ; AVANIER Schering Pu feo shes Sub President, ceO and Chairman «AN AWM, DUT B® f “Gregory . Hanson, CMA, MBA piece MAST Chief Financial Otficer = Philip 0. Livingston, M.D. Chief Scientific officer anes apmn AAIPHARMA EM ARENA & Wand chet Busnes oficer — JSventat in

Slide 6: Board of Directors
Mi Board of Directors J. David Hansen President, CEO and Chairman of MabVax Jeffrey F. Eisenberg Former CEO Noven Pharmaceuticals, Former Acting Gen Counsel IVAX Philip 0. Livingston, M.O. Chief Scientific Officer of MabVax Paul V. Maier Former CFO Sequenom Inc, Former St. VP & CFO Ligand Pharmaceut

Slide 7: Human Antibody (HuMab) Discovery Platform
Human Antibody (HuMab) Discovery Platform Proprietary Approach to the Discovery and Development of Novel Fully Human Antibody Therapy and Diagnostic Agents Focused Discovery Screening Optimized Therapy Fully human antibody ‘minimizes immunogenicity. Binding sequence reflects the patient's immune sys

Slide 8: Scientific Rationale
\ ’ { Scientific Rationa Say Lewis (te), the Hua 561 tara, isexgrezedin over 90% of panereate snd + CA19 91s considered a vatable adjnctn the diagnos, prognosis and montoring of + steis densely expressed in mits of opy numbers on toget umors ae ae ee) [A Pancreatic; 8 Colon. Lung. Blader © ovanan; B

Slide 9: Radioimmunotherapy (RIT) is Lead Clinical Program
Radioimmunotherapy (RIT) is Lead Clinical Program Mi Antibody-Based Therapeutic Agent to Treat Very Difficult Cancers Such as Pancreatic, Small Cell Lung and Colon + Target significantly over, expressed on cancers « Antibody has high degree of Established safety, specifiy, specificity for tumors. ‘a

Slide 10: Pipeline
Vi Se Protram Discovery Lead Op__PresND__Phasex_——__Phase2 ‘SialylLewis*for Pancreatic Cancer and CA19-9 malignancies including Lung and Gl Cancers Radioimmunotherapy (MVT1075) a Therapeutic (MVT-5873): Monotherapy > ‘Therapeutic (MVT-5873): + Chemo —SEEEESSS ImmunoPET imaging (MVT-2163) SEE Ta for

Slide 11: Safety and Efficacy
Safety and Efficacy

Slide 12: Safety findings and MTD
ing of transient elev typically resolved within a week ions in ALT, AST and rubin that Infusion reactions were mitigated with pre-medication and extended infusion times The MTD was established at 1 mg/kg + Al (1mg/kg) dosed every second week ue Bee Be ‘Ad (1me/ke) dosed every week Clears use in comb

Slide 13: Inclusion Criteria Established for Future Clinical Trials
M Inclusion Criteria Established for Future Clinical Trials * Phase 1a identified “responder subset” with at least 50% reduction in CA19-9 levels after single agent treatment. The “responder subset”: Are patients at screening that had CA19-9 levels < 2500 U/mL Stayed on treatment 4 months versus 1 m

Slide 14: Scientific and Medical Rationale for Imaging and RIT Dosing Strategy
M Scientific and Medical Rationale for Imaging and RIT Dosing Strategy + Antibodies are processed in the liver and spleen which play a central role in antibody clearance + Administration of cold antibody first saturates clearance mechanisms and reduces accumulation in liver and spleen + Cold-Hot dos

Slide 15: Cold-Hot Dosing Strategy Reduces Liver and Spleen Accumulation
Cold-Hot Dosing Strategy Reduces Liver and Spleen Accumulation Mi Data Support Using the Cold-Hot Dosing Strategy for RIT Program MiP images of two patients illustrating decreased liver SUV after cold pre-dose at day 7 2 Sx Sow EY Cencerttonatepcetin § 104 ne & 0 #17 «47 re IL . u dpe verre ener SUV

Slide 16: HuMab-5B1 Specifically Targets CA19-9 Positive Tumor Lesions
HuMab-5B1 Specifically Targets CA19-9 Positive Tumor Lesions Focal radiotracer uptake above background was observed in primary tumors and metastases from day 2 and continuously increased through day 7 + Day 7 tumor SUV,,,, Were as high as 101 g/mL FOG PET SUV, values “10 g/mL. + High focal uptake wa

Slide 17: Clinical Development Plan of Lead Asset MVT-1075 (RIT)
Clinical Development Plan of Lead Asset MVT-1075 (RIT)

Slide 18: One Cycle of Treatment
) One Cycle of Treatment Day 1 * MVT-5873 Cold Dose # ~Ahours wait Day 15 * MVT-1075 Hot Dose Day 57 Safety monitoring visits throughout and dosimetry completed day 8 RIT (MVT-1075) Phase 1a Clinical Trial First-In-Human Phase 1 + First patient dosed June 2017 with no OUTS * onrandomized opeael, doe

Slide 19: RIT (MVT-1075) Phase 1 Trial 2017
+ Firstin-Human dose June 2017 + Two clinical sites will ad enrollment: Honor Health nated) and MSKCC (planned 3) + Enroll ~3 patients in 2017 + Establish MTD in 2018 (estimate 12 patients) Y FDAAuthorization to |v First Clinical Site Proceed Initiated ¥ First in Human Dose RIT (MVT-1075) Phase 1 Tr

Slide 20: Milestones and News Flow
Milestones and News Flow Fe Orphon Dug | Phose te interim Preln @ AACR Intro Softy & PET Imaging Agent HuMab-581 Fe Optimized HuMab Programs ‘Aeerent Radiolmmunatherspy | 7 pase FIM Dawe ‘acy Designation AACR 2 ASCO Single Agent 7 Phase a @ ASCO Chemo Combination Complete 2 cohort | phase ta @ sna I

Slide 21: Corporate Development Update
Corporate Development Update

Slide 22: Recent Events and Strategy for Moving Ahead
Recent Events and Strategy for Moving Ahead Mi + Company has engaged credible global advisory bank to assist company in evaluating strategic options to unlock shareholder value Assist in evaluating transaction options Engaged in discussions with multiple large pharma companies Bring additional oppor

Slide 23: Financial Snapshot
M Financial Snapshot NASDAQ MBvx Key clinical asset has IP * protection ohare Bice ost * US patent for HuMab- Market Cap* $5.4M 5B1 issued October of 3M Avg. Daily Volume* 243K 2016 + Expires 2034 ‘Common Stock Outstanding/Public Float 10.6M/10.2M Corrésporiding foreign Preferred Stock (Common Equiv

Slide 24: Radioimmunotherapy (MVT-1075) program guided by recent clinical experience
dS + Radioimmunotherapy (MVT-1075) program guided by recent clinical experience 50 patients in three active clinical investigations with the HuMab-5B1 Antibody Data from completion of two Phase 1 studies accelerates RIT program First patient dosed in June Early readout of RIT clinical data by end of

Slide 25: MabVax Therapeutics
MabVa» therapeutics NASDAQ: MBVX ‘wirenabvatlae

Slide 26: Back up slides
i Back up slides

Slide 27: Value Indicators Suggest Potential for Significant Upside
M Value Indicators Suggest Potential for Significant Upside Radioimmunotherapy BALGETA (3a) NRRBSector * Xofigo, radiotherapeutic alpha particle + Betalutin for hematologic cancers in emitting product for castration-resistant Phase 1/2 Prostate cancer + Dosed 35 patients to date with + Acquired in 2

Slide 28: MVT-2163 Tumor Uptake Increases Over Time
M MVT-2163 Tumor Uptake Increases Over Tim Continuous uptake of MVT-2163 by primary tumor and metastases MVT-5873 blocking dose does not interfere with MVT-2163 lesion uptake “+ Omg +3mg = 17 mg+3mq = 47mg +39 ? ‘Average SUV Max ‘Tumor Blood Ratio (Day 7) ° 7 2 6 time post injection (days) of Dose o

Slide 29: Biodistribution Data Further Demonstrate Effectiveness of MVT-5873
Biodistribution Data Further Demonstrate Effectiveness of MVT-5873 Administration to reduce Non-Tumor SUV MVT-5873 pre-dose with 2 to 4 h delay to MVT-2163 administration reduces liver and spleen accumulation posted Doe cya AL Hinvaill Halli whe GUE if bs uy ILLS: “iy he Published in 2017 SNMMI Annu

Slide 30: Preclinical Studies Demonstrate Substantial Tumor Growth Suppression and Tumor Regression
Preclinical Studies Demonstrate Substantial Tumor Growt! pression and Tumor Regression Preferential Tumor Targeting with Minimal Distribution to Non-Tumor Tissues % my.CHX.AY-DTPA-SBA Biodistribution of 1” Lu-CHY-A"-DTPA-SBL

Slide 31: Orthotopic PDAC Model Demonstrates Tumor Regression
\ { Orthotopic PDAC Model Demonstrates Tumor Regre: Pre-treatment Post-treatment | cotaboration with Jason Stews, PhO. Member, Memorial loan Kettering Cancer Center, Vie Charman & Cie Atendng Departeat of Rasiogy 31

Slide 32: HuMab Represents Potential for New Treatment in Multiple Cancers
Cancer Type Pancreatic Colon & Rectum Small Cell Lung Cancer Stomach New Cases Per Year? 53,070 134,490 30,143 26,370 Deaths Per Year? 41,780 49,119 20,100 10,730 HuMab Represents Potential for New Treatment in Multiple Cancers 5 Year survivar’ 17% 65% 14% 31% Market Opportu: ‘Worl wide market has g

Slide 33: Robust Intellectual Property
Robust Intellectual Property Mi * 14 issued patents and 3 pending applications in the U.S. 13 issued US patents and 1 pending US application covering monovalent and polyvalent vaccines, methods of manufacture, methods of use issued US patent and 2 pending US applications covering monoclonal antibodi
Source: SEC EDGAR · 8-K filed Aug 24, 2017
More decks from MabVax Therapeutics Holdings Inc
Investor Presentation (October 2018)19 slides · Oct 22, 2018
Virtual Investor Conference (May 2018)25 slides · May 3, 2018
Investor Presentation (February 2018)24 slides · Feb 12, 2018
Investor Presentation (September 2017)33 slides · Sep 12, 2017
Investor Presentation (June 2017)23 slides · Jun 23, 2017
Technical Presentation (April 2017)57 slides · Apr 7, 2017